newsfilter
← Latest News
Business Wire·

Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

SPRB
  • Spruce Biosciences reports Q3 2026 financial results with cash and cash equivalents of $87.7 million as of September 30, 2026.
  • The BLA submission for tralesinidase alfa enzyme replacement therapy (TA-ERT) for MPS IIIB remains on track for December 2026.
  • An amended Avenue Loan Agreement increases Tranche 2 availability to $15 million \& extends the interest-only period through March 31, 2027.
  • The CRHX-101 program was separated into a new subsidiary named Adrenyx Biosciences to allow independent focus \& financing.
  • The TA-ERT Expanded Access Program initiated in November 2026 to treat approximately 10 U.S. participants with MPS IIIB.
  • The second Process Performance Qualification batch for TA-ERT is expected to be completed in December 2026.
  • The TrAnsform confirmatory study for TA-ERT is scheduled to initiate in December 2026 to evaluate efficacy on cognition.
  • Q3 2026 research and development expenses were $18.1 million, while general and administrative expenses were $5.8 million.
  • The company reported a net loss of $24.0 million for the quarter \& $52.5 million for the first nine months of 2026.
  • Adrenyx Biosciences secured $5 million in initial convertible notes with an option to issue up to $10 million total.
  • The distribution of Adrenyx common stock to Spruce shareholders is expected to be completed in the first half of 2027.
  • Spruce anticipates its current cash reserves will fund operations \& debt obligations into the second half of 2027.